Eclipsebio published a review by Ojalvo et al. describing the process of individualized neoantigen therapy across three phases involving formalin-fixed paraffin-embedded tumor blocks, whole blood for germline control and HLA typing, and a CAP/CLIA- and ISO13485-certified lab for histopathology, nucleic acid extraction, and next-generation sequencing.
Published
Signal category
Research & Knowledge
Quote
“In this review, Ojalvo et al. describe that process across three phases.”
— Eclipsebio team
Company
Eclipsebio
Next-generation assays. Data-driven analytics. RNA breakthroughs.
- Industry
- Biotechnology Research
- Location
- San Diego, US
- Company size
- 41 employees
Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including RNA design and custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: • RNA therapeutic sequence design informed by biological data through our eNAVIGATE platform • The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform • Multiomic characterization of small molecule and small oligonucleotide targets • Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs • Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.
Founded 2017